含溴结构域蛋白4在心血管疾病发病机制中的研究进展  

Progress in bromodomain-containing protein 4 in pathogenesis of cardiovascular diseases

作　　者：何磊 董泉彬 李菊香[1] HE Lei;DONG Quanbin;LI Juxiang(Department of Cardiovascular Medicine,The Second Affiliated Hospital of Nanchang University,Nanchang 330006,China)

机构地区：[1]南昌大学第二附属医院心血管内科,江西南昌330006

出　　处：《中国病理生理杂志》2024年第6期1141-1146,共6页Chinese Journal of Pathophysiology

基　　金：江西省重点研发计划项目(No.20202BBGL73069)。

摘　　要：心血管疾病(cardiovascular diseases)一直以来都是我国乃至全球疾病负担的主要原因,其生存率低,发病率一直呈现上升趋势[1]。据推测,我国目前心血管疾病患者高达3亿,导致的死亡人数约占全国死亡人数的40%,有数据显示,我国每年因心血管疾病产生的费用高达1700亿元,给医疗卫生保健资源带来了极大的负担[2-3]。心血管疾病涉及冠心病、心律失常、高血压、心肌病和心力衰竭等,虽然临床表现存在差异,但在发病机制中仍有许多相似之处。溴结构域和额外终端域(bromodomain and extra-terminal domain,BET)家族蛋白是一种表观遗传调控蛋白,由含溴结构域蛋白2(bromodomain-containing protein 2,BRD2)、BRD3、BRD4和睾丸特异性含溴结构域蛋白(testis-specific bromodomain-containing protein,BRDT)组成[4]。Bromodomain-containing protein 4(BRD4),a pivotal member of the bromodomain and extra-terminal domain(BET)family,is integral to the regulation of vital biological processes,including the cell cycle and gene expression.Studies have identified extensive expression of BRD4 in cardiomyocytes and its influence on various signaling pathways.The dysregulation of BRD4 leads to significant alterations in these pathways,culminating in pathological states such as myocardial inflammation,fibrosis,oxidative stress,and hypertrophy.These changes are instrumental in the onset and progression of cardiovascular diseases.This review summarizes the advances in research on BRD4 and its inhibitors in the context of cardiovascular diseases,with a focus on providing insights for precise therapeutic interventions.

关 键 词：心血管疾病 含溴结构域蛋白4 BRD4抑制剂 发病机制 

分 类 号：R54[医药卫生—心血管疾病] R363.2[医药卫生—内科学] R972[医药卫生—临床医学]